{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:24:50Z","timestamp":1787765090518,"version":"build-2784847793"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"name":"Melanoma Center Philanthropy Fund"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>\n                    Immune checkpoint inhibitors have transformed melanoma management; however, immune-related adverse events (irAEs) remain a major source of morbidity. Soluble immunomodulatory proteins are established biomarkers of autoimmune reactivity but have not been validated as predictors of irAEs. Evaluating their associations with irAEs may help identify patients at elevated risk and inform optimization of adjuvant checkpoint inhibitor therapy. Baseline serum samples from patients with resectable melanoma receiving adjuvant anti-programmed-death-1 therapy were obtained from the University of Pittsburgh Melanoma Center biospecimen repository (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    \u2005=\u200543). Soluble immunomodulatory proteins were quantified using Milliplex technology. Mean pretreatment protein levels were compared between patients with and without irAEs using two-sample\n                    <jats:italic toggle=\"yes\">t<\/jats:italic>\n                    -tests. Siglec-7 and Siglec-9 were elevated in patients who developed any irAE. Dermatitis was associated with elevated B7-H3 and major histocompatibility complex class I polypeptides. Thyroiditis was associated with elevated Nectin-4 and CXCL13 and reduced LAG3. Colitis was associated with elevated arginase. Hepatitis was associated with increased Galectin-3 and decreased Galectin-1, CD40L, CD226, and Nectin-4. Nectin-4 remained significant after false discovery rate adjustment in both thyroiditis and hepatitis, and CD226 remained significant in hepatitis. Potential biomarkers of recurrence-free survival (perforin, CD25, and ICOSL) and overall survival (FGL1) were also identified. Baseline soluble immunomodulatory proteins may predict the development of specific irAEs and survival outcomes from adjuvant anti-programmed-death-1 treatment. Notably, Nectin-4 may serve as a biomarker for both thyroiditis and hepatitis. Prospective studies are warranted to validate these findings.\n                  <\/jats:p>","DOI":"10.1097\/cmr.0000000000001122","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T08:00:15Z","timestamp":1783584015000},"page":"436-443","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Nectin-4 as predictive biomarker of immune-related adverse event subtypes in adjuvant anti-programmed-death-1 treatment of melanoma"],"prefix":"10.1097","volume":"36","author":[{"given":"Sabrina","family":"Bruno","sequence":"first","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Knight","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline J.","family":"Layding","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Health Data Science, University of Pittsburgh School of Public Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Health Data Science, University of Pittsburgh School of Public Health"},{"name":"Department of Medicine, Melanoma Program, UPMC Hillman Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter J.","family":"Storkus","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilit","family":"Karapetyan","sequence":"additional","affiliation":[{"name":"Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kirkwood","sequence":"additional","affiliation":[{"name":"Department of Medicine, Melanoma Program, UPMC Hillman Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"R1-20260826","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1200\/JCO.23.01136","article-title":"Systemic therapy for melanoma: ASCO guideline update.","volume":"41","author":"Seth","year":"2023","journal-title":"J Clin Oncol"},{"key":"R2-20260826","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.3390\/cancers15164125","article-title":"Adjuvant therapy for high-risk melanoma: an in-depth examination of the state of the field.","volume":"15","author":"Eljilany","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R3-20260826","doi-asserted-by":"crossref","first-page":"102556","DOI":"10.1016\/j.coi.2025.102556","article-title":"Autoimmune-related adverse events induced by immune checkpoint inhibitors.","volume":"94","author":"Sun","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"R4-20260826","doi-asserted-by":"crossref","first-page":"e20192179","DOI":"10.1084\/jem.20192179","article-title":"Understanding adverse events of immunotherapy: a mechanistic perspective.","volume":"218","author":"Burke","year":"2021","journal-title":"J Exp Med"},{"key":"R5-20260826","doi-asserted-by":"crossref","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors.","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"},{"key":"R6-20260826","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.2217\/fon-2020-0861","article-title":"Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data.","volume":"17","author":"Shimozaki","year":"2021","journal-title":"Future Oncol"},{"key":"R7-20260826","doi-asserted-by":"crossref","first-page":"17450","DOI":"10.1038\/s41598-025-02597-5","article-title":"The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis.","volume":"15","author":"Fu","year":"2025","journal-title":"Sci Rep"},{"key":"R8-20260826","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaut.2018.10.016","article-title":"The role of APRIL \u2013 a proliferation inducing ligand \u2013 in autoimmune diseases and expectations from its targeting.","volume":"95","author":"Baert","year":"2018","journal-title":"J Autoimmun"},{"key":"R9-20260826","doi-asserted-by":"crossref","first-page":"104234","DOI":"10.1016\/j.msard.2022.104234","article-title":"Cytokines\/chemokines and soluble immune checkpoint molecules in anti-GABAB receptor encephalitis.","volume":"68","author":"Qiao","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"R10-20260826","doi-asserted-by":"crossref","first-page":"e000146","DOI":"10.1136\/lupus-2016-000146","article-title":"Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus.","volume":"3","author":"Sullivan","year":"2016","journal-title":"Lupus Sci Med"},{"key":"R11-20260826","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/emm.2004.2","article-title":"Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis.","volume":"36","author":"Jung","year":"2004","journal-title":"Exp Mol Med"},{"key":"R12-20260826","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3803\/jkes.2006.21.2.116","article-title":"Expression of 4-1BB and 4-1BBL in graves\u2019 disease.","volume":"21","author":"Kim","year":"2006","journal-title":"J Korean Endocr Soc"},{"key":"R13-20260826","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1158\/1078-0432.CCR-08-1980","article-title":"Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma.","volume":"15","author":"Nevala","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R15-20260826","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.2517-6161.1964.tb00553.x","article-title":"An analysis of transformations.","volume":"26","author":"Box","year":"1964","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"R16-20260826","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"R17-20260826","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.3390\/ijms22115774","article-title":"Sialic scid\u2013Siglec axis in human immune regulation, involvement in autoimmunity and cancer and potential therapeutic treatments.","volume":"22","author":"Gianchecchi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R18-20260826","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00018-019-03288-x","article-title":"Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses.","volume":"77","author":"L\u00e4ubli","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"R19-20260826","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41392-022-01030-x","article-title":"CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect.","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"5Part A","key":"R20-20260826","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ijwd.2021.10.005","article-title":"Dermatologic immune-related adverse events: the toxicity spectrum and recommendations for management.","volume":"7","author":"Apalla","year":"2021","journal-title":"Int J Womens Dermatol"},{"key":"R21-20260826","doi-asserted-by":"crossref","first-page":"104077","DOI":"10.1016\/j.cellimm.2020.104077","article-title":"B7-H3: a promising therapeutic target for autoimmune diseases.","volume":"352","author":"Chen","year":"2020","journal-title":"Cell Immunol"},{"key":"R22-20260826","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/ced.14001","article-title":"Abnormal expression of the co-stimulatory molecule B7-H3 in lichen simplex chronicus is associated with expansion of Langerhans cells.","volume":"45","author":"Feng","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"R23-20260826","doi-asserted-by":"crossref","first-page":"633658","DOI":"10.3389\/fimmu.2021.633658","article-title":"Increased concentrations of circulating soluble MHC class I-related chain A (sMICA) and sMICB and modulation of plasma membrane MICA expression: potential mechanisms and correlation with natural killer cell activity in systemic lupus erythematosus.","volume":"12","author":"Hervier","year":"2021","journal-title":"Front Immunol"},{"key":"R24-20260826","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2147\/CCID.S506139","article-title":"Mendelian randomization combined with single-cell transcriptome analysis reveals the role of the key gene PCLAF in the pathogenesis of atopic dermatitis.","volume":"18","author":"Tao","year":"2025","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R25-20260826","doi-asserted-by":"crossref","first-page":"e2327145","DOI":"10.1001\/jamanetworkopen.2023.27145","article-title":"Extended follow-up of chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma.","volume":"6","author":"Goodman","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R26-20260826","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbrc.2023.07.058","article-title":"Molecular and structural basis of TIGIT: nectin-4 interaction, a recently discovered pathway crucial for cancer immunotherapy.","volume":"677","author":"Ganguli","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"R27-20260826","doi-asserted-by":"crossref","first-page":"850998","DOI":"10.3389\/fimmu.2022.850998","article-title":"Role of the CXCL13\/CXCR5 axis in autoimmune diseases.","volume":"13","author":"Pan","year":"2022","journal-title":"Front Immunol"},{"key":"R28-20260826","doi-asserted-by":"crossref","first-page":"bqae148","DOI":"10.1210\/endocr\/bqae148","article-title":"Sex-based differences in thyroid plasma B cell infiltration: implications for autoimmune disease susceptibility.","volume":"165","author":"Pereira Vasconcelos","year":"2024","journal-title":"Endocrinology"},{"key":"R29-20260826","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1530\/eje.0.1500225","article-title":"The role of CXCR5 and its ligand CXCL13 in the compartmentalization of lymphocytes in thyroids affected by autoimmune thyroid diseases.","volume":"150","author":"Aust","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"R30-20260826","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1038\/s41467-024-50007-7","article-title":"Start codon variant in LAG3 is associated with decreased LAG-3 expression and increased risk of autoimmune thyroid disease.","volume":"15","author":"Saevarsdottir","year":"2024","journal-title":"Nat Commun"},{"key":"R31-20260826","doi-asserted-by":"crossref","first-page":"e1524695","DOI":"10.1080\/2162402X.2018.1524695","article-title":"Clinical characterization of colitis arising from anti-PD-1 based therapy.","volume":"8","author":"Wang","year":"2019","journal-title":"Oncoimmunology"},{"key":"R32-20260826","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41577-024-01098-2","article-title":"The roles of arginases and arginine in immunity.","volume":"25","author":"Can\u00e8","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"R33-20260826","doi-asserted-by":"crossref","first-page":"G1323","DOI":"10.1152\/ajpgi.00499.2006","article-title":"Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease.","volume":"292","author":"Horowitz","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R34-20260826","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s12072-021-10151-4","article-title":"Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients.","volume":"15","author":"Biewenga","year":"2021","journal-title":"Hepatol Int"},{"key":"R35-20260826","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond.","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"R36-20260826","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3390\/biom15071007","article-title":"The Immune regulatory functions of CD226 and its implications in immune-mediated diseases.","volume":"15","author":"Liu","year":"2025","journal-title":"Biomolecules"},{"key":"R37-20260826","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.autrev.2008.11.009","article-title":"The immunological potential of galectin-1 and -3.","volume":"8","author":"Dhirapong","year":"2009","journal-title":"Autoimmun Rev"},{"key":"R38-20260826","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1073\/pnas.93.13.6737","article-title":"Expression of galectin-3 modulates T-cell growth and apoptosis.","volume":"93","author":"Yang","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R39-20260826","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5114\/ceji.2014.42135","article-title":"Perforin: an important player in immune response.","volume":"39","author":"Osi\u0144ska","year":"2014","journal-title":"Cent Eur J Immunol"},{"key":"R40-20260826","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3390\/biomedicines13020408","article-title":"Comprehensive analysis of granzymes and perforin family genes in multiple cancers.","volume":"13","author":"Mareboina","year":"2025","journal-title":"Biomedicines"},{"key":"R41-20260826","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40364-023-00508-2","article-title":"ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade.","volume":"11","author":"Ralser","year":"2023","journal-title":"Biomark Res"},{"key":"R42-20260826","doi-asserted-by":"crossref","first-page":"9581","DOI":"10.1158\/0008-5472.CAN-10-1379","article-title":"Melanoma cells express ICOS ligand to promote the activation and expansion of t-regulatory cells.","volume":"70","author":"Martin-Orozco","year":"2010","journal-title":"Cancer Res"},{"key":"R43-20260826","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/ijc.34281","article-title":"CD25: A potential tumor therapeutic target.","volume":"152","author":"Peng","year":"2023","journal-title":"Int J Cancer"},{"key":"R44-20260826","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0959-8049(01)00192-7","article-title":"Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma.","volume":"37","author":"Vuoristo","year":"2001","journal-title":"Eur J Cancer"},{"key":"R45-20260826","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13045-021-01161-8","article-title":"Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.","volume":"14","author":"Qian","year":"2021","journal-title":"J Hematol Oncol"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CMR.0000000000001122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:01:22Z","timestamp":1787763682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CMR.0000000000001122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000001122","relation":{},"ISSN":["0960-8931","1473-5636"],"issn-type":[{"value":"0960-8931","type":"print"},{"value":"1473-5636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"2026-04-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}